Scholarlink

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss. The disease progresses through early, intermediate, and advanced stages, with late forms including dry AMD (geographic atrophy) and wet AMD (choroidal neovascularization). Currently, there is no cure for dry AMD, which results from retinal pigment epithelium (RPE) cell loss. Induced pluripotent stem cell (iPSC)-based transplants offer a potential therapy by replacing atrophied RPE. This chapter outlines the manufacturing process, key parameters, and challenges of developing iPSC-derived RPE therapy. We engineered a clinical-grade iPSC-RPE patch using autologous cells from AMD patients. Starting from the patient blood, CD34+ cells were isolated, expanded, and reprogrammed using episomal plasmids. Twelve iPSC clones were generated, quality-tested, and three were selected for differentiation into mature RPE on a biodegradable scaffold. The final patch underwent QC assays for donor identity, sterility, and phenotype confirmation before transplantation. This work has led to a Phase I/IIa clinical trial to evaluate the safety and feasibility of auto-iPSC-RPE patches in AMD patients.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of a Manufacturing Process for Clinical Autologous hiPSC-Derived Retinal Pigment Epithelium

  • 章节

  • 发表日期：

    2025年

查看全文
  • Shekhar Jha,
  • Fang Hua,
  • Roba Dejene,
  • Sarmila Sarkar,
  • Ruchi Sharma,
  • Kapil Bharti

摘要

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss. The disease progresses through early, intermediate, and advanced stages, with late forms including dry AMD (geographic atrophy) and wet AMD (choroidal neovascularization). Currently, there is no cure for dry AMD, which results from retinal pigment epithelium (RPE) cell loss. Induced pluripotent stem cell (iPSC)-based transplants offer a potential therapy by replacing atrophied RPE. This chapter outlines the manufacturing process, key parameters, and challenges of developing iPSC-derived RPE therapy. We engineered a clinical-grade iPSC-RPE patch using autologous cells from AMD patients. Starting from the patient blood, CD34+ cells were isolated, expanded, and reprogrammed using episomal plasmids. Twelve iPSC clones were generated, quality-tested, and three were selected for differentiation into mature RPE on a biodegradable scaffold. The final patch underwent QC assays for donor identity, sterility, and phenotype confirmation before transplantation. This work has led to a Phase I/IIa clinical trial to evaluate the safety and feasibility of auto-iPSC-RPE patches in AMD patients.